SAREPTA THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
SAREPTA THERAPEUTICS, INC. (SRPT) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $156.95 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-26.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2020-02-26
- SAREPTA THERAPEUTICS, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2017 was $156.95M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|
| 2017-12-31 | $156.95M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |